RetroTherapy Overview

  • Founded
  • 2004
  • Status
  • Private
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $227K
Latest Deal Amount
  • Investors
  • 3

RetroTherapy General Information


Developer of ribonucleic acid based therapeutic designed to be used for the treatment of human genetic diseases. The company's therapy delivers therapeutic genes that can only be expressed in cells that contain viral RT, enabling healthcare practitioners to avail therapeutic drugs to selectively kill cells infected with retroviruses and preventing their spread.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Industries
Therapeutic Devices
Primary Office
  • 4519 Gretna Street
  • Bethesda, MD 20814
  • United States
+1 (301) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

RetroTherapy Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Grant 01-Jan-2015 $227K 0000 Completed Startup
6. Grant 01-Jan-2014 00000 0000 Completed Startup
5. Grant 01-Jan-2011 00000 0000 Completed Startup
4. Grant 01-Jan-2010 00000 0000 Completed Startup
3. Grant 01-Jan-2007 0000 Completed Startup
2. Early Stage VC 04-Jan-2005 $50K $50K Completed Startup
1. Grant Completed Startup
To view RetroTherapy’s complete valuation and funding history, request access »

RetroTherapy Executive Team (1)

Name Title Board Seat Contact Info
Lloyd Mitchell MD Founder, Chief Executive Officer & Chief Scientific Officer
To view RetroTherapy’s complete executive team members history, request access »

RetroTherapy Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
National Science Foundation Government 000 0000 000000 0
Maryland Stem Cell Research Fund Government 000 0000 000000 0
TEDCO Venture Capital Minority 000 0000 000000 0
To view RetroTherapy’s complete investors history, request access »